Risk Breakdown
Financial Exposure
Governance
Double Materiality
Supply Chain
Material Risks
ESG Targets & Commitments
| Topic | Target / Metric | Status |
|---|---|---|
| Human Rights in Supply Chain | HR clauses in all contracts | Commitment |
AI Risk Summary
**Financial Risk Summary – Balaxi Pharmaceuticals Limited** Balaxi's primary financial exposure stems from Extended Producer Responsibility (EPR) obligations, with a 6.5/10 risk score indicating material compliance uncertainty—the company has not yet clarified EPR applicability status, creating contingent liability risk if pharmaceutical packaging falls under scheduled waste rules. GHG and water intensity risks (both 5.0/10) are secondary concerns given the firm's wholesale/distribution model and zero reported direct emissions; however, Scope 3 supply chain emissions disclosure gaps leave unquantified carbon cost exposure that could materialize under tightened SEBI BRSR enforcement. The company faces regulatory compliance risk through mandatory SEBI BRSR P6 environmental disclosures and potential enforcement action if material ESG gaps persist, though current ₹0 crore estimated compliance cost suggests either preliminary assessment stage or potential underestimation of EPR remediation costs. Immediate priority: formalize EPR applicability assessment and quantify Scope 3 emissions to avoid future materiality restatements and regulatory sanctions.
Source: Balaxi Pharmaceuticals Limited BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.